⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9740335 | 0.71 | — | — | |
| SCHEMBL277478 | 0.69 | — | — | |
| SCHEMBL8993350 | 0.67 | — | — | |
| SCHEMBL10968946 | 0.65 | — | — | |
| SCHEMBL10968945 | 0.65 | — | — | |
| SCHEMBL11665930 | 0.65 | — | — | |
| SCHEMBL253659 | 0.64 | ZDHHC20 (0.39) | — | |
| SCHEMBL11293492 | 0.63 | — | — | |
| Acrylonitrile SCHEMBL10624079 | 0.63 | ALDH1A1 (0.45) | — | |
| SCHEMBL11501130 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| WO-2021046515-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | disclosed |
| EP-1838690-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | Devgen N.V. (BE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
| US-4012401-A | USED IN THE PRODUCTION OF POLYURETHANE FOAMS, CYANOALKOXYALKYL-MODIFIED | UNION CARBIDE CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |